Flaminia Pedretti
@flamipedretti.bsky.social
PARP inhibitors activate the STING pathway in HRD cells — but what happens when tumors develop resistance?
Find out more in our latest publication in Cancer Research :) led by Violeta Serra and Alba Llop at Vall d’Hebron Institute of Oncology, in collaboration with AstraZeneca.
Find out more in our latest publication in Cancer Research :) led by Violeta Serra and Alba Llop at Vall d’Hebron Institute of Oncology, in collaboration with AstraZeneca.
Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
PARP inhibitor sensitivity is associated with cGAS–STING–IFN signaling, which can be harnessed by combining PARP inhibitors with STING agonists to overcome acquired resistance and requires NK cells to...
aacrjournals.org
May 23, 2025 at 5:49 AM
PARP inhibitors activate the STING pathway in HRD cells — but what happens when tumors develop resistance?
Find out more in our latest publication in Cancer Research :) led by Violeta Serra and Alba Llop at Vall d’Hebron Institute of Oncology, in collaboration with AstraZeneca.
Find out more in our latest publication in Cancer Research :) led by Violeta Serra and Alba Llop at Vall d’Hebron Institute of Oncology, in collaboration with AstraZeneca.